In the present study, we showed that gefitinib modestly inhibited cell viability of lung cancer cell lines, H358 and A549, through inhibition of EGFR phosphorylation and the downstream signaling molecules, Akt and ERK1/2. This evidence concerns the gene MAPK3 and lung cancer.